相关实验视频
Updated: Jun 28, 2025

06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.7K
治疗心脏 Amyloidosis 的治疗方法
Dimitrios Bampatsias1, Abdirahman Wardhere, Mathew S Maurer
1Cardiac Amyloidosis Program, Department of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Current opinion in cardiology
|April 23, 2024
概括
针对跨氨酸氨基酸心肌病 (ATTR-CM) 的新疗法显示出有前途. 阿科拉米迪斯和帕蒂西兰证明了益处,而基因编辑和抗体疗法正在开发中,提供了超越目前治疗方法 (如tafamidis) 的希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 塔法米迪斯 (Tafamidis) 是唯一一款已批准的转氨基酸心肌病 (ATTR-CM) 的疾病修饰疗法.
- 在ATTR-CM治疗方面正在出现显著的进步,最近有3期试验结果和正在进行的后期研究.
- 本综述综合了ATTR-CM的当前和新兴治疗策略.
研究的目的:
- 审查目前ATTR-CM治疗的现状.
- 总结了新的ATTR-CM疗法最近的临床试验结果.
- 讨论ATTR-CM治疗开发的未来方向.
主要方法:
- 最近发表的第三期试验数据的审查 (ATTRibute-CM,APOLLO-B).
- 对正在进行的RNA沉声器,基因编辑 (CRISPR-Cas9) 和抗体疗法的第三阶段试验进行分析.
- 对ALXN2220.20等新药的早期试验结果的评估.
主要成果:
- 在ATTRibute-CM试验中,TTR稳定剂Acoramidis降低了死亡率和发病率.
- 在APOLLO-B试验中,Patisiran是一种RNA静音剂,在APOLLO-B试验中保留了功能能力和生活质量,尽管它没有被FDA批准用于ATTR-CM.
- 关于抗粉样抗体ALXN2220的早期数据表明,心肌损伤的逆转有可能发生.
结论:
- 针对ATTR-CM病理生理学的多个治疗点提供了新的治疗选择.
- 需要进一步的研究来比较不同治疗类别的疗效.
- 确定最有可能从特定治疗中受益的患者子组对于个性化医学至关重要.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159
Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574

